| Popis: |
Supplementary figure S1. JHU-029 HNC cells were left untreated or were treated for 48h with the EGFR inhibitor mAb cetuximab (10 mg/ml). Supplementary figure S2. JHU-029 were treated (48h), with cetuximab (10 mg/ml), IFNg (10 U/ml), cetuximab plus IFNg (10 mg/ml, 10 U/ml) and transcript level of SHP2 was analyzed with qPCR. Supplementary figure S3. JHU-029 (A-B), and PCI-13(C-D), cells were treated with control siRNA, EGFR siRNA, control siRNA plus cetuximab, and EGFR siRNA plus cetuximab, and levels of EGFR (A and C), and HLA class I (B and D), were determined by FACS. Supplementary figure S4. JHU-029 were treated (48h), with cetuximab (10 mg/ml), IFNg (10 U/ml), cetuximab plus IFNg (10 mg/ml, 10 U/ml) and transcript level of TAP1 (A), and LMP2 (B), were analyzed with qPCR. Supplementary figure S5. Characterization of HLA-A2:MAGE-3 complex mAb. |
